Literature DB >> 2827656

Different distribution of two types of angiotensin II-generating enzymes in the aortic wall.

H Okunishi1, M Miyazaki, T Okamura, N Toda.   

Abstract

Dog, monkey and human aortic tissues contained two distinct types of angiotensin II-generating enzymes; angiotensin converting enzyme (ACE) and chymostatin-sensitive angiotensin II-generating enzyme (CAGE). Endothelium, media and adventitia of canine thoracic aortae were separated using collagenase digestion, and determined for their ACE and CAGE activity. ACE activity was assayed by hippuryl-His-Leu cleavage. CAGE activity was estimated with ANG I as substrate in the presence of inhibitors of ACE and angiotensinases. His-Leu, the common product of both enzyme reactions, was fluorimetrically quantified after o-phthalaldehyde condensation. ACE localized mainly in endothelium, while CAGE distributed predominantly in adventitia. Similar results were obtained with human and monkey aortae. Such a contrasting distribution may indicate the distinct functional role of these two enzymes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2827656     DOI: 10.1016/0006-291x(87)90533-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Combination therapy with an angiotensin converting enzyme inhibitor and an angiotensin-II receptor antagonist for refractory essential hypertension.

Authors:  J D Bisognano; L D Horwitz
Journal:  West J Med       Date:  1998-04

2.  A new experimental approach in endothelium-dependent pharmacological investigations on isolated porcine coronary arteries mounted for impedance planimetry.

Authors:  L B Tankó; E O Mikkelsen; U Simonsen
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

3.  Captopril does not acutely modulate plasma endothelin-1 concentration in human congestive heart failure.

Authors:  O Grenier; F Pousset; R Isnard; H Kalotka; A Carayon; G Maistre; P Lechat; C Guerot; D Thomas; M Komajda
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

4.  Angiotensin converting enzyme activity is present in the endothelium-denuded aorta.

Authors:  E Pipili; V G Manolopoulos; J D Catravas; M E Maragoudakis
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

5.  Humoral and haemodynamic effects of idrapril calcium, the prototype of a new class of ACE-inhibitors, in essential hypertensive patients.

Authors:  S Taddei; L Ghiadoni; P Mattei; I Sudano; P Duranti; S Favilla; A Virdis; A Romagnoli; M Criscuoli; A Coppini
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

6.  Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277.

Authors:  W Wienen; N Hauel; J C Van Meel; B Narr; U Ries; M Entzeroth
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

7.  Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury.

Authors:  M F Prescott; R L Webb; M A Reidy
Journal:  Am J Pathol       Date:  1991-12       Impact factor: 4.307

Review 8.  Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.

Authors:  B Pitt; P Chang; P B Timmermans
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

9.  Cloning of the gene and cDNA for hamster chymase 2, and expression of chymase 1, chymase 2 and angiotensin-converting enzyme in the terminal stage of cardiomyopathic hearts.

Authors:  N Shiota; A Fukamizu; H Okunishi; S Takai; K Murakami; M Miyazaki
Journal:  Biochem J       Date:  1998-07-15       Impact factor: 3.857

10.  Investigation of the biochemical effects of renin inhibition in normal volunteers treated by an ACE inhibitor.

Authors:  D Chauveau; T T Guyenne; F Cumin; G Chatellier; P Corvol; J Ménard
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.